vs
Side-by-side financial comparison of Affinity Bancshares, Inc. (AFBI) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Affinity Bancshares, Inc. is the larger business by last-quarter revenue ($8.6M vs $5.5M, roughly 1.6× Taysha Gene Therapies, Inc.). Affinity Bancshares, Inc. runs the higher net margin — 24.9% vs -507.8%, a 532.7% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs 12.8%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 8.1%).
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
AFBI vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.6M | $5.5M |
| Net Profit | $2.1M | $-27.9M |
| Gross Margin | — | — |
| Operating Margin | 35.9% | -516.0% |
| Net Margin | 24.9% | -507.8% |
| Revenue YoY | 12.8% | 171.3% |
| Net Profit YoY | 58.5% | -48.3% |
| EPS (diluted) | $0.34 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.6M | $5.5M | ||
| Q3 25 | $8.4M | $0 | ||
| Q2 25 | $8.3M | $2.0M | ||
| Q1 25 | $7.8M | $2.3M | ||
| Q4 24 | $7.6M | $2.0M | ||
| Q3 24 | $8.0M | $1.8M | ||
| Q2 24 | $8.3M | $1.1M | ||
| Q1 24 | $7.3M | $3.4M |
| Q4 25 | $2.1M | $-27.9M | ||
| Q3 25 | $2.2M | $-32.7M | ||
| Q2 25 | $2.2M | $-26.9M | ||
| Q1 25 | $1.8M | $-21.5M | ||
| Q4 24 | $1.3M | $-18.8M | ||
| Q3 24 | $1.7M | $-25.5M | ||
| Q2 24 | $1.0M | $-20.9M | ||
| Q1 24 | $1.3M | $-24.1M |
| Q4 25 | 35.9% | -516.0% | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 34.1% | -1347.1% | ||
| Q1 25 | 30.8% | -930.5% | ||
| Q4 24 | 21.1% | -985.8% | ||
| Q3 24 | 28.5% | -1448.4% | ||
| Q2 24 | 16.2% | -1915.4% | ||
| Q1 24 | 24.0% | -713.3% |
| Q4 25 | 24.9% | -507.8% | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | 25.9% | -1353.6% | ||
| Q1 25 | 23.4% | -935.2% | ||
| Q4 24 | 17.7% | -929.0% | ||
| Q3 24 | 21.7% | -1427.5% | ||
| Q2 24 | 12.5% | -1882.0% | ||
| Q1 24 | 18.2% | -705.4% |
| Q4 25 | $0.34 | $-0.08 | ||
| Q3 25 | $0.34 | $-0.09 | ||
| Q2 25 | $0.33 | $-0.09 | ||
| Q1 25 | $0.28 | $-0.08 | ||
| Q4 24 | $0.21 | $-0.07 | ||
| Q3 24 | $0.26 | $-0.10 | ||
| Q2 24 | $0.16 | $-0.09 | ||
| Q1 24 | $0.20 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.9M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $127.0M | $246.9M |
| Total Assets | $881.7M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.9M | $319.8M | ||
| Q3 25 | $84.8M | $297.3M | ||
| Q2 25 | $89.7M | $312.8M | ||
| Q1 25 | $74.7M | $116.6M | ||
| Q4 24 | $41.4M | $139.0M | ||
| Q3 24 | $52.3M | $157.7M | ||
| Q2 24 | $50.4M | $172.7M | ||
| Q1 24 | $61.4M | $124.0M |
| Q4 25 | $127.0M | $246.9M | ||
| Q3 25 | $125.4M | $219.0M | ||
| Q2 25 | $124.1M | $248.7M | ||
| Q1 25 | $122.3M | $55.1M | ||
| Q4 24 | $129.1M | $71.5M | ||
| Q3 24 | $128.4M | $88.8M | ||
| Q2 24 | $125.1M | $108.9M | ||
| Q1 24 | $123.3M | $53.8M |
| Q4 25 | $881.7M | $343.3M | ||
| Q3 25 | $925.2M | $316.6M | ||
| Q2 25 | $933.8M | $333.3M | ||
| Q1 25 | $912.5M | $138.4M | ||
| Q4 24 | $866.8M | $160.4M | ||
| Q3 24 | $878.6M | $180.2M | ||
| Q2 24 | $873.6M | $200.4M | ||
| Q1 24 | $869.5M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.6M | $-26.7M |
| Free Cash FlowOCF − Capex | $11.2M | — |
| FCF MarginFCF / Revenue | 130.9% | — |
| Capex IntensityCapex / Revenue | 4.9% | — |
| Cash ConversionOCF / Net Profit | 5.46× | — |
| TTM Free Cash FlowTrailing 4 quarters | $20.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $-26.7M | ||
| Q3 25 | $3.7M | $-24.2M | ||
| Q2 25 | $3.8M | $-20.2M | ||
| Q1 25 | $1.9M | $-22.0M | ||
| Q4 24 | $6.8M | $-18.3M | ||
| Q3 24 | $4.1M | $-21.6M | ||
| Q2 24 | $619.0K | $-21.5M | ||
| Q1 24 | $1.2M | $-19.8M |
| Q4 25 | $11.2M | — | ||
| Q3 25 | $3.6M | $-24.3M | ||
| Q2 25 | $3.7M | — | ||
| Q1 25 | $1.8M | — | ||
| Q4 24 | $6.4M | $-18.3M | ||
| Q3 24 | $4.0M | $-21.6M | ||
| Q2 24 | $489.0K | $-21.7M | ||
| Q1 24 | $1.1M | $-19.9M |
| Q4 25 | 130.9% | — | ||
| Q3 25 | 43.3% | — | ||
| Q2 25 | 44.0% | — | ||
| Q1 25 | 22.7% | — | ||
| Q4 24 | 83.9% | -905.5% | ||
| Q3 24 | 49.5% | -1210.9% | ||
| Q2 24 | 5.9% | -1951.9% | ||
| Q1 24 | 14.8% | -584.5% |
| Q4 25 | 4.9% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 5.6% | 0.1% | ||
| Q3 24 | 1.7% | 2.0% | ||
| Q2 24 | 1.6% | 18.1% | ||
| Q1 24 | 1.8% | 4.1% |
| Q4 25 | 5.46× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 1.75× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 5.05× | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.91× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
